Get the Stockscreener App
1.13
5.83%
-0.07
Ikena Oncology Inc stock is traded at $1.13, with a volume of 144.82K.
It is down -5.83% in the last 24 hours and down -16.30% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$1.20
Open:
$1.132
24h Volume:
144.82K
Relative Volume:
1.17
Market Cap:
$54.53M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.6933
EPS:
-1.63
Net Cash Flow:
$-80.16M
1W Performance:
-14.39%
1M Performance:
-16.30%
6M Performance:
-33.53%
1Y Performance:
-16.91%
1-Day Range:
$1.09
$1.18
1-Week Range:
$1.09
$1.32
52-Week Range:
$1.09
$1.94
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.13 | 54.53M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges - Investing.com
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Ikena Oncology: Investor Caution as Dividend Payments Remain Unlikely - TipRanks
Ikena Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ikena Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Ikena Oncology, Inc. SEC 10-K Report - TradingView
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 11.8% - MarketBeat
Discovering February 2025's Promising Penny Stocks On US Exchanges - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Stock Price Down 0.7%Here's Why - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Ikena Oncology Inc (IKNA) - SETE News
Understanding the Risks of Investing in Ikena Oncology Inc (IKNA) - Knox Daily
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
How former leaders of a sold-off biotech company landed their drugs again - The Business Journals
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Scrip
US Penny Stocks To Watch In January 2025 - Simply Wall St
What Direction Does Ikena Oncology Inc (NASDAQ: IKNA) Analysts Think The Company Will Take? - Stocks Register
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - MSN
Is Amazon a Buy, Sell, or Hold in 2025? - Yahoo! Voices
Ikena Oncology and Inmagene Biopharmaceuticals to Merger - citybiz
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Inmagene takes back-door route to Nasdaq listing - The Pharma Letter
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - Marketscreener.com
Five things you need to know, and a Chrismukkah throwback - The Business Journals
Mitek Systems (NASDAQ:MITK) Rating Increased to Strong-Buy at StockNews.com - Defense World
Helius Medical Technologies, Inc. Announces First PoNS System Sale to VA Healthcare SystemOn December 23, 2024, Helius Medical Technologies, Inc. (NASDAQ:HSDT) disclosed its successful sale of the first Portable Neuromodulation Stimulator (PoNS) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
What is HC Wainwright’s Forecast for CVE:NDA Q1 Earnings? - Defense World
Ikena Oncology Enters into Merger Agreement with Inmagene BiopharmaceuticalsOn December 23, 2024, Ikena Oncology, Inc. (NASDAQ: IKNA) announced a significant development as it entered into a Merger Agreement with Inmagene Biopharmaceuticals. - Defense World
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
Moving iMage Technologies Reports Results of Annual Meeting On December 19, 2024, Moving iMage Technologies, Inc. (NYSEAMERICAN: MITQ) held its annual meeting of stockholders. The company disclosed details regarding the meeting through an 8-K - Defense World
D-Wave Quantum Inc. (NYSE:QBTS) Receives $5.63 Consensus Price Target from Analysts - Defense World
Salesforce (NYSE:CRM) Stock Price Down 0% Following Insider Selling - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush - Defense World
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding - Marketscreener.com
Ikena Oncology's (IKNA) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Ikena Oncology Shares Rise After Merger Announcement With Inmagene Biopharmaceuticals - MarketWatch
Ikena Oncology and Inmagene Biopharmaceuticals announces merger - MSN
Ikena Oncology, Inmagene Biopharmaceuticals to Merge - MarketWatch
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis - The Manila Times
iKena Oncology, Inmagene enter definitive merger agreement, private placement - TipRanks
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewswire
Questor Technology (OTCMKTS:QUTIF) Trading Down 13% – Should You Sell? - Defense World
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):